溢多利(300381.SZ)：與Fornia公司簽訂技術轉讓合同 引入國際先進水平的生物酶製劑表達平台、菌種及技術
格隆匯 11 月 20日丨溢多利(300381.SZ)公佈，公司(“甲方”)是主要在生物醫藥和生物農牧領域從事生物酶製劑、甾體激素原料藥、功能性飼料添加劑等產品的研發、生產、銷售和服務，並向客户提供整體生物技術解決方案的專業生物技術企業。生物酶製劑是一種具有催化功能的生物製品，可廣泛應用於飼料、食品、能源、洗滌、製藥、紡織、保健品等多個領域。
為加快開發新產品並提高部分酶種的技術指標，提升產品應用效果，公司於2020年11月19日與Fornia BioSolutions, Inc. (“Fornia公司”或“乙方”)在廣東省珠海市簽訂了《技術轉讓合同》，約定乙方將其擁有的創新型EG-673系列中性纖維素酶產品、創新型Xyl-591系列木聚糖酶產品、創新性GLA-789糖化酶產品、309G2 Amds黑麴黴表達系統、創新型EG-531系列中性纖維素酶G627產品及植酸酶-502變體系列等技術轉讓給甲方，甲方受讓並支付相應的使用費。雙方約定，技術使用費總額為326萬美元。
Fornia 公司是一家美國的高科技生物技術企業，該公司具有完整的微生物和生物酶製劑的研發平台，擁有高通量的篩選設備和大數據分析系統，可高效率地開展生物酶的定向進化、重組表達、微生物菌株的修飾和改良、發酵工藝優化等科研工作。信譽良好，具備履行合同義務的能力。
此次技術轉讓合同涉及六項技術轉讓。其中一項309G2 Amds黑麴黴表達系統是生物酶製劑的表達平台，增加了公司生物酶製劑高效發酵生產平台種類，有利於提升公司生物酶製劑發酵生產效率，降低生產成本。其中兩項用於飼料添加劑領域：植酸酶-502變體系列進一步提升了植酸酶的耐温性，提升了飼料在高温制粒下的酶活保留率，提高產品性價比；創新型Xyl-591系列木聚糖酶產品提升了抗酸性100%，提高產品應用效果，降低客户使用成本。其中三項用於其他工業酶領域：創新型EG-673系列中性纖維素酶產品、創新型EG-531系列中性纖維素酶G627產品主要應用於紡織行業中的織物改良和洗滌行業中的織物整理及去污力提升，有利於公司開拓生物酶製劑產品在紡織和洗滌行業的應用；創新性GLA-789糖化酶產品主要應用於食品行業中澱粉糖和能源酒精生產，可以幫助客户提高生產穩定性，提升產品質量，降低生產成本。
通過引入以上國際先進水平的生物酶製劑表達平台、菌種及技術，有利於提升公司在生物酶製劑的研發水平，有利於公司進一步開拓飼用及其他工業酶製劑應用市場，整體提升公司生物酶製劑產品的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
